ConductScience.org, home

Paper41328347

Advancements in CRISPR-based therapies for ocular pathologies: from disease mechanisms to intervention strategies.

Li Q and 7 others. Theranostics, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Advancements in CRISPR-based therapies for ocular pathologies: from disease mechanisms to intervention strategies. Papers, record 41328347. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41328347

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advancements in CRISPR-based therapies for ocular pathologies: from disease mechanisms to intervention strategies.
PubMed
Journal
Theranostics
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-20
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li QQinghua
2Bao QQingdong
3Zhao SSihan
4Wu FFan
5Li YYang
6Wang KKaiyuan
7Li WWenlong
8Gao HHua

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Genetic TherapyMajor topic
Eye DiseasesMajor topic
Gene EditingMajor topic
CRISPR-Cas SystemsMajor topic
Humans
Animals

References192

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133432198Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice.Nat Biotechnol2021https://conductscience.org/library/papers/33432198PubMed
238942756PAM-flexible Engineered FnCas9 variants for robust and ultra-precise genome editing and diagnostics.Nat Commun2024https://conductscience.org/library/papers/38942756PubMed
319279343Primary open-angle glaucoma.N Engl J Med2009https://conductscience.org/library/papers/19279343PubMed
429055361The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research.Ophthalmology2017https://conductscience.org/library/papers/29055361PubMed
526751509CRISPR-Cas adaptation: insights into the mechanism of action.Nat Rev Microbiol2016https://conductscience.org/library/papers/26751509PubMed
634100716Start codon disruption with CRISPR/Cas9 prevents murine Fuchs' endothelial corneal dystrophy.Elife2021https://conductscience.org/library/papers/34100716PubMed
730664785Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10.Nat Med2019https://conductscience.org/library/papers/30664785PubMed
824146387Glaucoma and the applications of carbonic anhydrase inhibitors.Subcell Biochem2014https://conductscience.org/library/papers/24146387PubMed
938466284Exploring Heparanase Levels in Tears: Insights From Herpes Simplex Virus-1 Keratitis Patients and Animal Studies.Invest Ophthalmol Vis Sci2024https://conductscience.org/library/papers/38466284PubMed
1017345604Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype.Hum Mutat2007https://conductscience.org/library/papers/17345604PubMed
1126310166Introduction to the Retina.Prog Mol Biol Transl Sci2015https://conductscience.org/library/papers/26310166PubMed
1238582513Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo.Adv Sci (Weinh)2024https://conductscience.org/library/papers/38582513PubMed
1333152914CRISPR/Cas13: A potential therapeutic option of COVID-19.Biomed Pharmacother2020https://conductscience.org/library/papers/33152914PubMed
1435991315Effective splicing restoration of a deep-intronic ABCA4 variant in cone photoreceptor precursor cells by CRISPR/SpCas9 approaches.Mol Ther Nucleic Acids2022https://conductscience.org/library/papers/35991315PubMed
1532891680Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.J Control Release2020https://conductscience.org/library/papers/32891680PubMed
1626422227Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.Cell2015https://conductscience.org/library/papers/26422227PubMed
1738518771CRISPR editing of anti-anemia drug target rescues independent preclinical models of retinitis pigmentosa.Cell Rep Med2024https://conductscience.org/library/papers/38518771PubMed
1832157225CRISPR treatment inserted directly into the body for first time.Nature2020https://conductscience.org/library/papers/32157225PubMed
1928392220Modeling Developmental and Tumorigenic Aspects of Trilateral Retinoblastoma via Human Embryonic Stem Cells.Stem Cell Reports2017https://conductscience.org/library/papers/28392220PubMed
2025307992Congenital stationary night blindness: an analysis and update of genotype-phenotype correlations and pathogenic mechanisms.Prog Retin Eye Res2015https://conductscience.org/library/papers/25307992PubMed

See all 192 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41328347

GET https://conductscience.org/api/papers/v1/41328347/references?page=2